DR. FRANK LITVACK, MD
Medical Practice in Los Angeles, CA

2007026, Nov 22, 2007

Apr 4, 2007

11/696360

Theodore Parker - Danville CA, US
Thai Nguyen - Santa Clara CA, US
John Shanley - Redwood City CA, US
Frank Litvack - Los Angeles CA, US

Conor Medsystems, LLC. - Menlo Park CA

A61F 2/06, A61K 31/337, A61K 31/4353, A61K 38/28, A61P 9/00

424426000, 424423000, 514291000, 514004000, 514449000, 514789000

Methods and devices are provided for the delivery of therapeutic agents which reduce myocardial tissue damage due to ischemia and anti-restenotic agents which inhibit restenosis following a cardiac procedure such as stent implantation. The anti-ischemia agents are delivered to the myocardial tissue over an administration period sufficient to achieve reduction in ischemic or reperfusion injury of the myocardial tissue. The anti-restenotic agents are delivered over an administration period sufficient to reduce the re-narrowing of a blood vessel following a cardiac procedure such as implantation of a device. Preferred anti-restenotic drugs are those that do not reduce the beneficial effects provided by the anti-ischemic drug, such as drugs that do not act on the mammalian target of rapamycin (mTOR).

2012007, Mar 22, 2012

Aug 19, 2011

13/214095

John F. Shanley - Emerald Hills CA, US
Stephen H. Diaz - Palo Alto CA, US
Alan E. Shluzas - Redwood City CA, US
Frank Litvack - Los Angeles CA, US

A61B 17/04

606232

One embodiment is directed to a system for providing surgical access across a wall of a tissue structure, comprising: a delivery member having proximal and distal ends; a plurality of helical members, each having proximal and distal ends and a helical shape, each proximal end coupled to the delivery member distal end, each distal end extending distally of the delivery member distal end; a plurality of anchor members removably coupled to the helical member distal ends; and a plurality of suture members coupled distally to a portion of one of the anchor members and extending proximally to a position wherein at least a portion of each may be freely manipulated by an operator; wherein upon rotation of the delivery member in a first direction, the helical members and coupled anchor members are advanced across at least a portion of the wall of the tissue structure, pulling along the distal portions of the suture members in a deployed suture pattern which remains coupled to the anchor member.

2006012, Jun 8, 2006

Mar 14, 2005

11/079967

John Shanley - Redwood City CA, US
Frank Litvack - Los Angeles CA, US
Theodore Parker - Danville CA, US
Thai Nguyen - Santa Clara CA, US

Conor Medsystems, Inc. - Menlo Park CA

A61F 2/06

623001420

An expandable medical device includes a plurality of elongated struts, forming a substantially cylindrical device which is expandable from a cylinder having a first diameter to a cylinder having a second diameter. A plurality of different beneficial agents can be loaded into different openings within the struts for delivery to the tissue. For treatment of conditions such as restenosis, different beneficial agents are loaded into different openings in the device to address different biological processes involved in restenosis and are delivered at different release kinetics matched to the biological process treated. The different beneficial agents may also be used to address different diseases, such as restenosis and acute myocardial infarction from the same drug delivery device.

2012007, Mar 29, 2012

Aug 19, 2011

13/214088

John F. Shanley - Emerald Hills CA, US
Stephen H. Diaz - Palo Alto CA, US
Alan E. Shluzas - Redwood City CA, US
Frank Litvack - Los Angeles CA, US

A61B 17/04

606139, 606232

One embodiment is directed to a system for providing surgical access across a wall of a tissue structure, comprising: a delivery member having proximal and distal ends; a first helical member having proximal and distal ends and a helical shape, the proximal end coupled to the delivery member distal end, the distal end extending distally of the delivery member distal end; an anchor member removably coupled to the helical member distal end; and a suture member coupled distally to a portion of the anchor member and extending proximally to a position wherein at least a portion of it may be freely manipulated by an operator; wherein the proximal end of the suture member extends proximally beyond the deployed suture pattern into a local suture length storage reservoir coupled to the delivery member, the reservoir containing an additional length of suture and being configured such that upon rotation of the delivery member in the first direction, the anchor member pulls along the distal portion of the suture member causing at least a portion of the additional length of suture to be extended out from the local suture length storage reservoir, and causing the distal portion of the suture member to form a deployed suture pattern which remains coupled to the anchor member.

2007019, Aug 16, 2007

Feb 6, 2007

11/671642

Theodore Parker - Danville CA, US
John Shanley - Redwood City CA, US
Frank Litvack - Los Angeles CA, US

Conor Medsystems, Inc. - Menlo Park CA

A61F 2/06

623001420, 623001150

A method for reducing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti-restenotic agent, such as paclitaxel, from the stent to vascular tissue in need of treatment in a controlled and extended drug release profile for a period of at least 60 days in vivo. The in vivo release profile is determined by in vivo animal experiments involving implanting a series of stents in animals, explanting the stents from the animals at selected time points, and extracting remaining drug from the explanted stents.

2004014, Jul 22, 2004

Nov 10, 2003

10/705151

Frank Litvack - Los Angeles CA, US
Theodore Parker - Danville CA, US
John Shanley - Redwood City CA, US

Conor Medsystems, Inc.

A61F002/00

424/423000

A method and apparatus for the local delivery of therapeutic agents reduces myocardial tissue damage due to ischemia. A local delivery device is used for delivery of the therapeutic agents into a coronary artery which feeds the ischemic myocardial tissue. According to one example, an implantable medical device for delivering insulin locally to myocardial tissue includes a therapeutic dosage of insulin in a biocompatible polymer affixed to a stent. The therapeutic dosage of insulin is released from the stent at a therapeutic dosage and over an administration period effective to reduce ischemic injury of the myocardial tissue.

2008017, Jul 17, 2008

Oct 17, 2006

11/582521

Peter S. Brown - Palo Alto CA, US
Lawrence John Voss - San Jose CA, US
Frank Litvack - Los Angeles CA, US

Conor Medsystems, Inc. - Menlo Park CA

A61M 29/00, A61M 31/00, A61M 37/00

60410304

A rapid exchange balloon catheter has a short rapid exchange length for faster catheter exchanges the balloon catheter includes a balloon structure having a balloon leg connected to a catheter shaft. Marker bands may be provided in the balloon leg for facilitating measurement of a dimension of physiological features. A stiffening wire extending longitudinally at least partially into the balloon leg may be provided to supplement and control the flexibility characteristics of the balloon leg.

2012008, Apr 12, 2012

Aug 19, 2011

13/214128

John F. Shanley - Emerald Hills CA, US
Frank Litvack - Los Angeles CA, US

A61B 17/06

606223

One embodiment is directed to a method for providing surgical access across a wall of a tissue structure, comprising: advancing a helical needle into the wall of the tissue structure such that the needle pulls an intercoupled suture member across the wall to form a deployed suture pattern, the deployed suture pattern being characterized in that: the portion of the suture member encapsulated by the wall of the tissue structure is substantially helical in formation and represents a number of helical loops that is greater than about one helical loop, and is less than about three helical loops; portions of the suture member on either side of the wall are in a slack configuration such that tension in the suture member arising from the encapsulated portion pulls in additional length from the slack configuration on either side of the wall to accommodate expansion of the substantially helical encapsulated portion.

2006000, Jan 5, 2006

Aug 26, 2005

11/213570

Frank Litvack - Los Angeles CA, US
Theodore Parker - Danville CA, US
John Shanley - Redwood City CA, US

Conor Medsystems, Inc. - Menlo Park CA

A61M 31/00, A61F 2/00

424423000, 604500000

A method and apparatus for the local delivery of therapeutic agents reduces myocardial tissue damage due to ischemia. A local delivery device is used for delivery of the therapeutic agents into a coronary artery which feeds the ischemic myocardial tissue. According to one example, an implantable medical device for delivering insulin locally to myocardial tissue includes a therapeutic dosage of insulin in a biocompatible polymer affixed to a stent. The therapeutic dosage of insulin is released from the stent at a therapeutic dosage and over an administration period effective to reduce ischemic injury of the myocardial tissue.

2006017, Aug 10, 2006

Jan 4, 2006

11/325223

Theodore Parker - Danville CA, US
John Shanley - Redwood City CA, US
Brett Trauthen - Newport Beach CA, US
Frank Litvack - Los Angeles CA, US
Stephen Diaz - Palo Alto CA, US

Conor Medsystems, Inc. - Menlo Park CA

A61F 2/06

623001420

A method for decreasing the level of restenosis following a stent placement medical intervention involves the continuous administration of a dose of an anti-restenotic agent, such as paclitaxel, from the stent to vascular tissue in need of treatment in a controlled, extended, and substantially linear drug release profile. The method of substantially linear extended release increases the therapeutic effectiveness of administration of a given dosage. In one example, a method of reducing restenosis includes delivering paclitaxel from a stent to an artery at a minimum release rate of 1 percent of the total dosage of paclitaxel on the stent per day throughout an entire administration period from the time of implantation of the stent until the time that substantially all the paclitaxel is released from the stent.